Jublia

GPTKB entity

Statements (53)
Predicate Object
gptkbp:instance_of gptkb:pharmaceuticals
gptkbp:application applied directly to the affected toenail
gptkbp:approves gptkb:FDA
gptkbp:available_in gptkb:various_countries
gptkbp:brand gptkb:Jublia
gptkbp:class antifungal
gptkbp:clinical_trial Phase III
demonstrated efficacy in treating onychomycosis
gptkbp:clinical_use applied once daily
gptkbp:condition onychomycosis
gptkbp:contraindication hypersensitivity to efinaconazole
gptkbp:dosage_form gptkb:liquid
gptkbp:drug_interactions none significant reported
gptkbp:duration 24 hours
48 weeks
gptkbp:form topical solution
gptkbp:healthcare 2014-07-24
https://www.w3.org/2000/01/rdf-schema#label Jublia
gptkbp:ingredients gptkb:efinaconazole
gptkbp:invention patented
gptkbp:is_effective_against shown in clinical trials
gptkbp:label includes instructions for use
gptkbp:manufacturer gptkb:Valeant_Pharmaceuticals
gptkbp:marketed_as gptkb:2014
gptkbp:mechanism_of_action inhibits fungal cell membrane synthesis
gptkbp:packaging bottle with applicator
gptkbp:patient_education important for understanding treatment
gptkbp:patient_population adults
gptkbp:pharmacokinetics minimal systemic absorption
gptkbp:pharmacy_availability widely available
gptkbp:previous_name no
gptkbp:price varies by pharmacy
gptkbp:provides_guidance_on recommended for mild to moderate cases
gptkbp:requires gptkb:true
available online
gptkbp:research showed improvement in nail appearance
gptkbp:safety_features generally well tolerated
gptkbp:safety_measures for external use only
gptkbp:service_frequency once daily
gptkbp:side_effect allergic reaction
skin irritation
redness
stinging
burning sensation
gptkbp:storage room temperature
gptkbp:treatment around 50%
improved nail health
topical antifungal therapy
gptkbp:treatment_limitations not for use in children
gptkbp:type_of_care important for treatment success
gptkbp:used_for treating toenail fungus
gptkbp:bfsParent gptkb:Valeant_Pharmaceuticals
gptkbp:bfsLayer 6